Matthew J. Bock

Matthew J. Bock

Auto-generated profile, based on publicly available information

Matthew J. Bock

Division of Pediatric Cardiology, Department of Pediatrics, University of California, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Circulation
Verified
Journal Article
Open access
RSRobert Shaddy
Robert Shaddy
MBMichael Burch
Michael Burch
Paul F. KantorPaul F. Kantor
Paul F. Kantor
SSSusan Solar-Yohay
Susan Solar-Yohay
TGTania Garito
Tania Garito
Damien BonnetDamien Bonnet
Damien Bonnet
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD). METHODS: Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up. The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain. The change from baseline to 52 weeks in NT-proBNP (N-terminal pro–B-type natriuretic peptide) was an exploratory end point. RESULTS: A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188). At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47–0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72–1.14]; P =0.42). At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups. Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children. CONCLUSIONS: In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point. However, both treatment arms showed clinically meaningful improvements over 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02678312.

25 July 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
MBMatthew J. Bock
Matthew J. Bock
GVGabrielle R. Vaughn
Gabrielle R. Vaughn
PCPeter Chau
Peter Chau
JBJennifer A. Berumen
Jennifer A. Berumen
JNJohn J. Nigro
John J. Nigro
EIElizabeth G Ingulli
Elizabeth G Ingulli
The COVID‐19 pandemic has influenced organ transplantation decision making. Opinions regarding the utilization of coronavirus disease‐2019 (COVID‐19) donors are mixed. We hypothesize that COVID‐19 infection of deceased solid organ transplant donors does not affect recipient survival. All deceased solid organ transplant donors with COVID‐19 testing results from March 15, 2020 to September 30, 2021 were identified in the OPTN database. Donors were matched to recipients and stratified by the COVID‐19 test result. Outcomes were assessed between groups. COVID‐19 test results were available for 17 694 donors; 150 were positive. A total of 269 organs were transplanted from these donors, including 187 kidneys, 57 livers, 18 hearts, 5 kidney‐pancreases, and 2 lungs. The median time from COVID‐19 testing to organ recovery was 4 days for positive and 3 days for negative donors. Of these, there were 8 graft failures (3.0%) and 5 deaths (1.9%). Survival of patients receiving grafts from COVID‐19‐positive donors is equivalent to those receiving grafts from COVID‐19‐negative donors (30‐day patient survival = 99.2% COVID‐19 positive; 98.6% COVID‐19 negative). Solid organ transplantation using deceased donors with positive COVID‐19 results does not negatively affect early patient survival, though little information regarding donor COVID‐19 organ involvement is known. While transplantation is feasible, more information regarding COVID‐19‐positive donor selection is needed.

4 April 2017 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MBMatthew J. Bock
Matthew J. Bock
EPElfriede Pahl
Elfriede Pahl
PRPaolo G. Rusconi
Paolo G. Rusconi
GBGerard J. Boyle
Gerard J. Boyle
JPJohn J. Parent
John J. Parent
DBDaniel Bernstein
Daniel Bernstein

11 April 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
WCWanqiu Chen
Wanqiu Chen
CWChenguang Wang
Chenguang Wang
ZYZhi-Xue Yang
Zhi-Xue Yang
FZFeng Zhang
Feng Zhang
WWWei Wen
Wei Wen
CWCharles Wang
Charles Wang
Mesenchymal stromal cells (MSCs) have great value in cell therapies. The MSC therapies have many challenges due to its inconsistent potency and limited quantity. Here, we report a strategy to generate induced MSCs (iMSCs) by directly reprogramming human peripheral blood mononuclear cells (PBMCs) with OCT4, SOX9, MYC, KLF4, and BCL-XL using a nonintegrating episomal vector system. While OCT4 was not required to reprogram PBMCs into iMSCs, omission of OCT4 significantly impaired iMSC functionality. The omission of OCT4 resulted in significantly downregulating MSC lineage specific and mesoderm-regulating genes, including SRPX, COL5A1, SOX4, SALL4, TWIST1. When reprogramming PBMCs in the absence of OCT4, 67 genes were significantly hypermethylated with reduced transcriptional expression. These data indicate that transient expression of OCT4 may serve as a universal reprogramming factor by increasing chromatin accessibility and promoting demethylation. Our findings represent an approach to produce functional MSCs, and aid in identifying putative function associated MSC markers.

1 June 2019 in Cardiology in the Young
Verified
Journal Article
Closed access
RKRachel Koo
Rachel Koo
JLJennifer Lo
Jennifer Lo
MBMatthew J. Bock
Matthew J. Bock
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

6 January 2021 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
DBDavid W. Bearl
David W. Bearl
RCRyan Cantor
Ryan Cantor
DKDevin Koehl
Devin Koehl
JGJeffrey G. Gossett
Jeffrey G. Gossett
MBMatthew J. Bock
Matthew J. Bock
CRChitra Ravishankar
Chitra Ravishankar